Previous 10 | Next 10 |
Xenetic Biosciences (NASDAQ: XBIO ) has filed another preliminary prospectus , this time for an offering of 1,649,113 common shares, each with an accompanying five-year warrant to purchase one common share at an assumed combined price of $9.02. More news on: Xenetic Biosciences, Inc., Hea...
Gainers: Camber Energy (NYSEMKT: CEI ) +107% . Acacia Communications (NASDAQ: ACIA ) +35% . Electrameccanica Vehicles (NASDAQ: SOLO ) +26% . Xenetic Biosciences (NASDAQ: XBIO ) +16% . iFresh Inc. (NASDAQ: IFMK ) +15% . Atreca (NASDAQ: BCEL ) +15% . Pareteum Corporation (NASDAQ:...
Gainers: Oasmia Pharmaceutical OASM +76% . Xenetic Biosciences (NASDAQ: XBIO ) +41% . Tyme Technologies TYME +22% . Gol Linhas Aereas Inteligentes S.A. GOL +19% . BIOLASE (NASDAQ: BIOL ) +16% . OHR Pharmaceutical (NASDAQ: OHRP ) +15% . Cool Holdings (NASDAQ: AWSM...
Gainers : Foresight Autonomous (NASDAQ: FRSX ) +65% . Highpower International (NASDAQ: HPJ ) +39% . Avid Bioservices (NASDAQ: CDMO ) +32% . Phunware (NASDAQ: PHUN ) +30% . Xenetic Biosciences (NASDAQ: XBIO ) +27% . Motorcar Parts of America (NASDAQ: MPAA ) +25% . Unum Therapeutics (N...
Xenetic Biosciences ( XBIO +7.3% ) has announced one-for-twelve reverse stock split of its issued and outstanding common stock. More news on: Xenetic Biosciences, Inc., Healthcare stocks news, Read more ...
FRAMINGHAM, MA / ACCESSWIRE / June 24, 2019 / Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"), today announced it will effect a one-for-twelve reverse stock split of its issued and outstanding common stock. Pursuant to the Certificate of Change filed with the Secret...
Gainers: Eltek (NASDAQ: ELTK ) +70% . Iovance Biotherapeutics (NASDAQ: IOVA ) +33% . Adverum Biotechnologies (NASDAQ: ADVM ) +25% . Charah Solutions (NYSE: CHRA ) +19% . KEMET Corporation (NYSE: KEM ) +17% . Mirati Therapeutics (NASDAQ: MRTX ) +16% . Danaos Corporation (NYSE: D...
Xenetic Biosciences (NASDAQ: XBIO ): Q1 net loss of ~$1.3M More news on: Xenetic Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Company on track to close acquisition of novel XCART platform technology Entry into CAR T space positions company to drive significant momentum over the course of 2019 advancing XCART platform technology XCART initially being developed to target B-cell lymphomas and has th...
Represents key appointment to bolster scientific and oncology expertise as Company prepares to advance XCART platform technology Internationally renowned expert in the treatment of leukemia, myelodysplastic syndrome, multiple myeloma and other lymphoproliferative diseases, both with...
News, Short Squeeze, Breakout and More Instantly...
Xenetic Biosciences Inc. Company Name:
XBIO Stock Symbol:
NASDAQ Market:
Xenetic Biosciences Inc. Website:
Company's Board of Directors Appoint James F. Parslow to Interim Chief Executive Officer FRAMINGHAM, MA / ACCESSWIRE / May 22, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technolog...
Ongoing preclinical studies with multiple data readouts expected throughout remainder of 2024 Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors Ended the qu...
Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors Ended the year with $9.0 million of cash to fund operations FRAMINGHAM, MA / ACCESSWIRE / March 22, 2024 /...